The estimated Net Worth of Ventures Fund Llc Mrl is at least $3.18 Million dollars as of 2 July 2018. Ventures Mrl owns over 25,000 units of Telesis Bio Inc stock worth over $3,184,955 and over the last 6 years Ventures sold TBIO stock worth over $0.
Ventures has made over 1 trades of the Telesis Bio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Ventures bought 25,000 units of TBIO stock worth $325,000 on 2 July 2018.
The largest trade Ventures's ever made was buying 25,000 units of Telesis Bio Inc stock on 2 July 2018 worth over $325,000. On average, Ventures trades about 25,000 units every 0 days since 2018. As of 2 July 2018 Ventures still owns at least 1,873,503 units of Telesis Bio Inc stock.
You can see the complete history of Ventures Mrl stock trades at the bottom of the page.
Ventures's mailing address filed with the SEC is ONE MERCK DRIVE, , WHITEHOUSE STATION, NJ, 08889.
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk und Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Inc executives and other stock owners filed with the SEC include: